Social risk phenotypes linked to hepatocellular carcinoma diagnosis and survival

A statewide study of 4,117 Indiana patients with hepatocellular carcinoma identified six social risk phenotypes that differed in stage at diagnosis, receipt of curative therapy, and two-year mortality; the most advantaged group had higher early diagnosis and curative treatment rates while an "unseen and uninsured" group had the poorest outcomes.

This study analyzed cancer registry data from Indiana to examine how social and structural factors cluster and relate to hepatocellular carcinoma (HCC) outcomes. Researchers used latent class analysis on 4,117 complete cases drawn from an original cohort of 4,877 patients diagnosed from 2009–2020. They identified six distinct social risk phenotypes and grouped them into three pragmatic risk tiers based on stage at diagnosis, receipt of curative therapy, and two‑year mortality. The authors noted limits including single-state data and missing or proxy measures of some social determinants. Key findings: - Six latent social phenotypes were identified, labeled (among others) "minimal barriers" (class 1) and "unseen and uninsured" (class 6). - Class 1 had the highest rates of early-stage diagnosis and curative therapy (early-stage ~55.4%; curative therapy 24.4%). - Class 6 had the lowest early-stage diagnosis (39.7%), the lowest curative therapy receipt (10.5%), and the highest two-year mortality (83.6%); class 6 showed an adjusted odds ratio of 4.12 (95% CI 3.06–5.54) for two-year death compared with class 1. - The six classes were further grouped into three risk tiers: Tier 1 (classes 1–3, lower risk), Tier 2 (classes 4–5, moderate risk), and Tier 3 (class 6, high risk). - The analysis used routinely available registry measures—insurance, occupation, marital status, neighborhood social deprivation index, and distance to care—but authors cautioned these may not capture lived experience or all structural barriers. Summary: The study found clear gradients in diagnosis, treatment, and survival across empirically derived social phenotypes of HCC patients in Indiana, with socially connected and insured groups showing better outcomes and a distinct, socially disconnected group showing markedly worse outcomes. The authors report that external validation and additional measurement of social determinants are needed to assess generalizability and to refine how these phenotypes could inform targeted engagement strategies.